Table 1.
Characteristics of treated brain metastases (N = 190).
| Metastasis characteristic | SRS (N = 92) | FSRT (N = 98) | p for comparison |
|---|---|---|---|
| Pretreatment metastasis volume, cm3 | p < 0.001# | ||
| Median (IQR) | 0.23 (0.12–0.50) | 1.42 (0.34–4.41) | |
| Mean (range) | 0.40 (0.07–2.38) | 4.66 (0.07–61.98) | |
| Pretreatment metastasis diameter, cm | p < 0.001# | ||
| Median (IQR) | 1.0 (0.8–1.3) | 1.8 (1.1–2.7) | |
| Mean (range) | 1.1 (0.6–2.1) | 2.1 (0.6–6.1) | |
| Histology, n (%) | p = 0.005§ | ||
| Melanoma | 51 (55.4%) | 32 (32.7%) | |
| Lung | 9 (9.8%) | 17 (17.3%) | |
| Breast | 4 (4.3%) | 16 (16.3%) | |
| Renal | 15 (16.3%) | 15 (15.3%) | |
| Other | 13 (14.1%) | 18 (18.4%) | |
| Single Dose, Gy | p < 0.001# | ||
| Median (IQR) | 20.0 (18.0–20.0) | 4.0 (4.0–6.0) | |
| Mean (range) | 19.3 (16.0–20.0) | 4.5 (2.0–7.0) | |
| Total Dose, Gy | p < 0.001# | ||
| Median (IQR) | 40.0 (35.0–40.0) | ||
| Mean (range) | 39.1 (28.0–54.0) | ||
| BED12-LQC, Gy | p < 0.001# | ||
| Median (IQR) | 41.0 (36.0–41.0) | 52.4 (52.4–52.8) | |
| Mean (range) | 39.2 (31.0–41.0) | 52.2 (36.6–63.0) | |
| BED2-LQ, Gy | p < 0.001# | ||
| Median (IQR) | 220.0 (180.0–220.0) | 120.0 (120.0–144.0) | |
| Mean (range) | 205.8 (144.0–220.0) | 125.4 (72.0–157.5) | |
| Former Whole-brain radiotherapy, n (%) | p = 0.351§ | ||
| Yes | 19 (20.7%) | 15 (15.3%) | |
| No | 73 (79.3%) | 83 (84.7%) |
IQR, interquartile range; BED12−LQC, Biologically effective dose for an alpha/beta ratio of 12, linear-quadratic-cubic model; BED2−LQ, Biologically effective dose for an alpha/beta ratio of 2, linear-quadratic model.
#
T-Test.
§
Fisher's exact text.